Check Your Eligibility Free Consultation (Prospective Patients) Starting July 1, 2026 , Medicare Part D covers Wegovy, Zepbound, and Foundayo for weight loss through the new GLP-1 Bridge program
However, losing as little as 5% of body weight can have health benefits
With all of this in mind, Kennedy is likely to unleash risky peptides soon
Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E
Current clinical evidence suggests that starting GLP-1 therapy in gastroparesis requires careful medical evaluation and baseline gastric function assessment, not automatic exclusion from treatment
Brain health should also be incorporated, using cognitive testing and imaging to assess whether these therapies influence neurodegenerative risk